Our previous study demonstrated the potential of alpha-2-macroglobulin (A2M) and clusterin (CLU) as novel diagnostic uEV biomarkers for bladder cancer (BC) through a comparative analysis of uEVs acquired from patients with BC before and after surgery using an antibody array [18]. This evidence concerns the gene CLU and urinary bladder cancer.